Duke logo

Samus: PU-H71-01-002 Phase 1b PUH71 Ruxolitinib PMF, post-PV MF and post-ET MF - Clinical Trial

What is the Purpose of this Study?

We are doing this study to find out if the drug PU-H71 combined with uxolitinib for patients with myelofibrosis is safe and tolerable.

What is the Condition Being Studied?

Myelofibrosis

Who Can Participate in the Study?

Adults who:
- Have a confirmed diagnosis of myelofibrosis, including PMF, post-PV MF, and post-ET MF
- Have an Eastern Cooperative Oncology Group performance status of 0-2

Age Group
Adults

What is Involved?

If you choose to join this study, you will:
- Get the drug, PU-H71, in your vein over 1 hour for three consecutive weeks and Ruxolitinib will be given twice daily
- Have multiple physical exams, ECGs, MRIs, and blood samples collections
- Have multiple bone marrow biopsies/aspirates

Study Details

Full Title
A Phase Ib Study of Ruxolitinib in Combination with PUH71 for the treatment of Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (post- PV MF), and Post-Essential Thrombocythemia MF (post-ET MF)
Principal Investigator
Hematologist
Protocol Number
IRB:PRO00090837
NCT:NCT03373877
Phase
Phase I
ClinicalTrials.gov
Contact the Duke Recruitment Innovation Center
studyrecruitment@duke.edu
or
919-681-5698